Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
In a recent study the researchers used the approach to measure levels of eight proteins in a breast cancer tissue section using a total of 180 antibody spots.
NanoString also beat analyst estimates on the top and bottom lines, and upped its revenue guidance for the year based primarily on collaboration revenues.
The subsidiary of Sysmex is evaluating two liquid biopsy technologies for their abilities to monitor patient response to chemotherapy in breast cancer patients.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
Total revenue for the quarter was $85.5 million compared to $82 million in Q2 2016, while net loss shrank to $2.7 million or $.08 per share.
The Australian molecular diagnostics firm received 265 test samples during the quarter, including 140 tests issued to Ohio State University as part of an agreement.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.